Effect of liraglutide biosimilar vs. reference liraglutide on weight reduction in T2DM patients with obesity: post hoc analysis of phase III trial

Table 5 Glycemic parameters across T2DM patients with obesity (Inter group)

Sr. no	Parameter	Treatment	Week 24 (Mean ± SD)	p value
1	HbA1c	Biosimilar Liraglutide	7.22 ± 1.92	0.898
1	HbA1c	Reference Liraglutide	7.12 ± 2.14	0.898
2	FPG	Biosimilar Liraglutide	112.64 ± 35.28	0.433
2	FPG	Reference Liraglutide	118.02 ± 44.19	0.433
3	PPBG	Biosimilar Liraglutide	166.10 ± 51.94	0.178
3	PPBG	Reference Liraglutide	174.29 ± 61.40	0.178

ISSN: 3059-4057